Clinical Trial Search

Phase 3 N=325 Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Spondyloarthropathies

Primary: Assessment in Axial Spondyloarthritis International Society 20 % (ASAS20) Response Criteria at Week 12 — 38.3; 57.7; 63.6; 60.6 percentage of participants — p==0.004

UCB BIOSCIENCES GmbH Results Dec 2013 19.4% serious AE View details

Phase 3 N=54 A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

Primary: Time-adjusted Area Under the Curve (AUC) (i.e., Weighted Mean) for 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at the End of Each 28-day Treatment…

GlaxoSmithKline Results Dec 2013 0.0% serious AE View details

Phase 3 N=20 A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Cardiac Edema

Primary: Body Weight — -1.68; -2.14 Kg

Otsuka Pharmaceutical Co., Ltd. Results Dec 2013 5.0% serious AE View details

Phase 3 N=84 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Angioedema

Primary: Time to Onset of Symptom Relief (TOSR) — 2.5; 4.6 Hours — p=0.142

Shire Results Dec 2013 2.9% serious AE View details

Phase 3 N=160 A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

Vaginitis · Infectious Vaginosis

Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants

Janssen-Cilag, S.A. Results Dec 2013 0.0% serious AE View details

Phase 3 N=87 The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Venous Thromboembolism

Primary: Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE) — 2; 2; 1; NA participants

Mary Knudson, M.D. Results Dec 2013 0.0% serious AE View details

Phase 3 N=246 The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Primary: Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Placebo — 7.34; 7.33; 0.98; -0.38 Units on a scale

Novartis Pharmaceuticals Results Dec 2013 2.6% serious AE View details

Phase 3 N=199 Weekly Zinc Chelate Supplementation on Children's Growth

Short Stature

Primary: Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period. — 0.04; -0.08; 0.10; 0.02 Z-Score — p=<0.05

Federal University of São Paulo Results Dec 2013 0.0% serious AE View details

Phase 3 N=4,203 Age-Related Eye Disease Study 2 (AREDS2)

Age-related Macular Degeneration · Cataract

Primary: Development of Advanced AMD in People at Moderate to High Risk for Progression. — 493; 468; 507; 472 Eyes — p=<0.013

National Eye Institute (NEI) Results Dec 2013 47.3% serious AE View details

Phase 3 N=285 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

Chronic Low Back Pain

Primary: Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS) — 1.2; 23.0 scores on a scale

AbbVie (prior sponsor, Abbott) Results Dec 2013 0.6% serious AE View details

Phase 3 N=45 Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement

Malocclusion

Primary: The Rate of Orthodontic Movement of a Maxillary Canine Tooth Being Distalized to Close an Extraction Space. — 0.27; 0.18 mm/week

OrthoAccel Technologies Inc. Results Dec 2013 0.0% serious AE View details

Phase 3 N=308 Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

Chronic Low Back Pain

Primary: Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS) — 1.1; 18.0 scores on a scale

AbbVie (prior sponsor, Abbott) Results Dec 2013 0.5% serious AE View details

Phase 3 N=31 Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

Bipolar Disorder

Primary: Time to Treatment for Emerging Symptoms of a Mood Relapse — 17.8; 15.9 weeks

University Hospitals Cleveland Medical Center Results Dec 2013 0.0% serious AE View details

Phase 3 N=108 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

Acromegaly

Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…

Ipsen Results Dec 2013 14.4% serious AE View details

Phase 3 N=150 Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System

Typical Atrial Flutter

Primary: Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure — 3 participants

Abbott Medical Devices Results Dec 2013 2.2% serious AE View details